Systematic literature review of long-term efficacy data for topical psoriasis treatments

References

• Rendon A, Schakel K. Psoriasis pathogenesis and treatment. Int J Mol Sci. 2019;20(6):1475.
   PubMed Web of Science ®Google Scholar
• Boehncke WH, Schön MP. Psoriasis. Lancet. 2015;386(9997):983–994.
   PubMed Web of Science ®Google Scholar
• National Institute for Health and Care Excellence. Psoriais: assessment and management; 2012. [11 December 2020]. Available from: https://www.nice.org.uk/guidance/cg153
   Google Scholar
• Girolomoni G, Calzavara Pinton P, Cristaudo A, et al. Back to the future: a new topical approach for mild-to-moderate psoriasis. G Ital Dermatol Venereol. 2018;153(3):375–382.
   PubMed Web of Science ®Google Scholar
• Yeung H, Takeshita J, Mehta NN, et al. Psoriasis severity and the prevalence of major medical comorbidity: a population-based study. JAMA Dermatol. 2013;149(10):1173–1179.
   PubMed Web of Science ®Google Scholar
• Kim WB, Jerome D, Yeung J. Diagnosis and management of psoriasis. Can Fam Physician. 2017;63(4):278–285.
   PubMed Web of Science ®Google Scholar
• Brandon A, Mufti A, Gary Sibbald R. Diagnosis and management of cutaneous psoriasis: a review. Adv Skin Wound Care. 2019;32(2):58–69.
   PubMed Web of Science ®Google Scholar
• Segaert S, Calzavara-Pinton P, de la Cueva P, et al. Long-term topical management of psoriasis: the road ahead. J Dermatolog Treat. 2020:1–10.DOI:10.1080/09546634.2020.1729335
   Web of Science ®Google Scholar
• Carrascosa JM, Theng C, Thaçi D. Spotlight on topical long-term management of plaque psoriasis. Clin Cosmet Investig Dermatol. 2020;13:495–498.
   PubMed Web of Science ®Google Scholar
• Wollenberg A, Ehmann LM. Long term treatment concepts and proactive therapy for atopic eczema. Ann Dermatol. 2012;24(3):253–260.
   PubMed Web of Science ®Google Scholar
• Reitamo S, Mandelin J, Remitz A. Long-term management of atopic dermatitis: evidence from recent clinical trials. Clinical Investigation. 2011;1(1):171–177.
   Google Scholar
• Wollenberg A, Reitamo S, Girolomoni G, et al. Proactive treatment of atopic dermatitis in adults with 0.1% tacrolimus ointment. Allergy. 2008;63(7):742–750.
   Web of Science ®Google Scholar
• Mrowietz U. Implementing treatment goals for successful long-term management of psoriasis. J Eur Acad Dermatol Venereol. 2012;26 (Suppl 2):12–20.
   PubMed Web of Science ®Google Scholar
• Paul C, Gallini A, Archier E, et al. Evidence-based recommendations on topical treatment and phototherapy of psoriasis: systematic review and expert opinion of a panel of dermatologists. J Eur Acad Dermatol Venereol. 2012;26 (Suppl 3):1–10.
   PubMedGoogle Scholar
• Elmets CA, Korman NJ, Prater EF, et al. Joint AAD-NPF Guidelines of care for the management and treatment of psoriasis with topical therapy and alternative medicine modalities for psoriasis severity measures. J Am Acad Dermatol. 2021;84(2):432–470.
   PubMed Web of Science ®Google Scholar
• Maul JT, Anzengruber F, Conrad C, et al. Topical treatment of psoriasis vulgaris: the Swiss treatment pathway. Dermatology. 2021;6:1–13.
   Google Scholar
• Körber A, Wilsmann-Theis D, Augustin M, et al. Topische therapie bei psoriasis vulgaris - ein behandlungspfad. J Dtsch Dermatol Ges. 2019;17 (Suppl 4):3–14.
   Google Scholar
• Augustin M, Mrowietz U, Bonnekoh B, et al. Topical long-term therapy of psoriasis with vitamin D3 analogues, corticosteroids and their two compound formulations: position paper on evidence and use in daily practice. J Dtsch Dermatol Ges. 2014;12(8):667–682.
   Web of Science ®Google Scholar
• Mason AR, Mason J, Cork M, et al. Topical treatments for chronic plaque psoriasis. Cochr Datab Syst Rev. 2013;(3):Cd005028.
   PubMed Web of Science ®Google Scholar
• Gerritsen MJ, Van De Kerkhof PC, Langner A. Long-term safety of topical calcitriol 3 microg g(-1) ointment. Br J Dermatol. 2001;144 (Suppl 58):17–19.
   PubMedGoogle Scholar
• Ramsay CA, Berth-Jones J, Brundin G, et al. Long-term use of topical calcipotriol in chronic plaque psoriasis. Dermatology. 1994;189(3):260–264.
   PubMed Web of Science ®Google Scholar
• Medicines.org.uk. Enstilar Cutaneous Foam - Summary of Product Characteristics (SmPC); 2020. [08/12/20]. Available from: https://www.medicines.org.uk/emc/product/2139
   Google Scholar
• Alora-Palli MB, Perkins AC, Van Cott A, et al. Efficacy and tolerability of a cosmetically acceptable coal tar solution in the treatment of moderate plaque psoriasis: a controlled comparison with calcipotriene (calcipotriol) cream. Am J Clin Dermatol. 2010;11(4):1–83.
   PubMed Web of Science ®Google Scholar
• Dahri GMM, Mughal SA, Qureshi MA, et al. Placebo controlled study on the efficacy and safety of calcipotriol in the treatment of mild to moderate psoriasis. Medical Forum Monthly. 2012;23(11):44–47.
   Google Scholar
• De Korte JVDV, Sprangers PGM, Damstra MAG, et al. Comparison of twice-daily calcipotriol ointment with once-daily short-contact dithranol cream therapy: quality-of-life outcomes of a randomized controlled trial of supervised treatment of psoriasis in a day-care setting. British Journal of Dermatology. 2007;158(2):375–381.
   PubMed Web of Science ®Google Scholar
• Levine D, Even-Chen Z, Lipets I, et al. Pilot, multicenter, double-blind, randomized placebo-controlled bilateral comparative study of a combination of calcipotriene and nicotinamide for the treatment of psoriasis. J Am Acad Dermatol. 2010;63(5):775–781.
   PubMed Web of Science ®Google Scholar
• Ortonne JP, van de Kerkhof PC, Prinz JC, et al. 0.3% Tacrolimus gel and 0.5% Tacrolimus cream show efficacy in mild to moderate plaque psoriasis: results of a randomized, open-label, observer-blinded study. Acta Derm Venereol. 2006;86(1):29–33.
   PubMed Web of Science ®Google Scholar
• Roussaki-Schulze AV, Kouskoukis C, Klimi E, et al. Calcipotriol monotherapy versus calcipotriol plus UVA1 versus calcipotriol plus narrow-band UVB in the treatment of psoriasis. Drugs Exp Clin Res. 2005; 200531(5):169–174.
   PubMedGoogle Scholar
• Sharma V, Kaur I, Kumar B. Calcipotriol versus coal tar: a prospective randomized study in stable plaque psoriasis. Int J Dermatol. 2003;42(10):834–838.
   PubMed Web of Science ®Google Scholar
• Siadat AH, Iraji F, Khodadadi M, et al. Topical nicotinamide in combination with calcipotriol for the treatment of mild to moderate psoriasis: A double-blind, randomized, comparative study. Adv Biomed Res. 2013;2:90.
   PubMedGoogle Scholar
• Takahashi H, Tsuji H, Ishida-Yamamoto A, et al. Comparison of clinical effects of psoriasis treatment regimens among calcipotriol alone, narrowband ultraviolet B phototherapy alone, combination of calcipotriol and narrowband ultraviolet B phototherapy once a week, and combination of calcipotriol and narrowband ultraviolet B phototherapy more than twice a week. J Dermatol. 2013;40(6):424–427.
   PubMed Web of Science ®Google Scholar
• van de Kerkhof PC, van der Valk PG, Swinkels OQ, et al. A comparison of twice-daily calcipotriol ointment with once-daily short-contact dithranol cream therapy: a randomized controlled trial of supervised treatment of psoriasis vulgaris in a day-care setting. Br J Dermatol. 2006;155(4):800–807.
   PubMed Web of Science ®Google Scholar
• Vena GA, Cassano N, Alessandrini G, et al. Treatment of mild to moderate plaque psoriasis with calcitriol ointment applied with or without a dosing device. Eur J Inflamm. 2007;5(2):89–95.
   Web of Science ®Google Scholar
• Wang BL, Sun WB, Yang LW, et al. Sequential use of calcipotriol betamethasone cream and calcipotriol ointment for psoriasis. J Clin Dermatol. 2017;46(5):353–355.
   Google Scholar
• Barker JN, Berth-Jones J, Groves R, et al. Calcium homeostasis remains unaffected after 12 weeks' therapy with calcitriol 3 microg/g ointment; no correlation with extent of psoriasis. J Dermatolog Treat. 2003;14(1):14–21.
   PubMedGoogle Scholar
• Carboni I, de Felice C, Bergamin A, et al. Topical use of calcitriol 3 microg/g ointment in the treatment of mild-to-moderate psoriasis: results from an open-label study. J Eur Acad Dermatol Venerol. 2005;19(s3):11–13.
   PubMed Web of Science ®Google Scholar
• Zhu X, Wang B, Zhao G, et al. An investigator-masked comparison of the efficacy and safety of twice daily applications of calcitriol 3 microg/g ointment vs. calcipotriol 50 microg/g ointment in subjects with mild to moderate chronic plaque-type psoriasis. J Eur Acad Dermatol Venereol. 2007;21(4):466–472.
   PubMed Web of Science ®Google Scholar
• Katayama I, Ohkawara A, Ohkido M, et al. High-concentration (20 mug/g) tacalcitol ointment therapy on refractory psoriasis vulgaris with low response to topical corticosteroids. Eur J Dermatol. 2002;12(6):553–557.
   PubMed Web of Science ®Google Scholar
• Lahfa M, Mrowietz U, Koenig M, et al. Calcitriol ointment and clobetasol propionate cream: a new regimen for the treatment of plaque psoriasis. Eur J Dermatol. 2003;13(3):261–265.
   PubMed Web of Science ®Google Scholar
• Griffiths CE, Stein Gold L, Cambazard F, et al. Greater improvement in quality of life outcomes in patients using fixed-combination calcipotriol plus betamethasone dipropionate aerosol foam versus gel: results from the PSO-ABLE study. Eur J Dermatol. 2018;28(3):356–363.
   PubMed Web of Science ®Google Scholar
• Khandpur S, Sahni K. An open label prospective randomized trial to compare the efficacy of coal tar-salicylic Acid ointment versus calcipotriol/betamethasone dipropionate ointment in the treatment of limited chronic plaque psoriasis. Indian J Dermatol. 2014;59(6):579–583.
   PubMed Web of Science ®Google Scholar
• Paul C, Leonardi C, Menter A, et al. Erratum to: calcipotriol plus betamethasone dipropionate aerosol foam in patients with moderate-to-severe psoriasis: sub-group analysis of the PSO-ABLE study. Am J Clin Dermatol. 2017;18(4):591.
   PubMed Web of Science ®Google Scholar
• Paul C, Leonardi C, Menter A, et al. Calcipotriol plus betamethasone dipropionate aerosol foam in patients with moderate-to-severe psoriasis: sub-group analysis of the PSO-ABLE study. Am J Clin Dermatol. 2017;18(3):405–411.
   PubMed Web of Science ®Google Scholar
• Paul C, Stein Gold L, Cambazard F, et al. Calcipotriol plus betamethasone dipropionate aerosol foam provides superior efficacy vs. gel in patients with psoriasis vulgaris: randomized, controlled PSO-ABLE study. J Eur Acad Dermatol Venereol. 2017;31(1):119–126.
   PubMed Web of Science ®Google Scholar
• Paul C, Stein Gold L, Cambazard F, et al. More rapid improvement in quality of life with fixed-combination calcipotriene plus betamethasone dipropionate aerosol foam vs. topical suspension (PSO-ABLE study in patients with psoriasis vulgaris) [Journal: Conference Abstract]. British Journal of Dermatology. 2016;175:213–214.
   Web of Science ®Google Scholar
• Saraceno R, Andreassi L, Ayala F, et al. Efficacy, safety and quality of life of calcipotriol/betamethasone dipropionate (Dovobet) versus calcipotriol (Daivonex) in the treatment of psoriasis vulgaris: a randomized, multicentre, clinical trial. J Dermatolog Treat. 2007;18(6):361–365.
   PubMed Web of Science ®Google Scholar
• Sardar Singh H, Narayana S. Vijayarangam S. Comparison of efficacy of calcipotriol and betamethasone combination with betamethasone alone in plaque psoriasis. Nat J Physiol Pharm Pharmacol. 2017;7(1):99–102.
   Google Scholar
• Afreen H, Islam A, Alam M, et al. A comparative study of once daily tazarotene versus combination of tazarotene and betamethasone valerate in the treatment of plaque psoriasis. J Pak Assoc Dermatol. 2019;29(1):93–100.
   Google Scholar
• Angelo JS, Kar BR, Thomas J. Comparison of clinical efficacy of topical tazarotene 0.1% cream with topical clobetasol propionate 0.05% cream in chronic plaque psoriasis: a double-blind, randomized, right-left comparison study. Indian J Dermatol Venereol Leprol. 2007;73(1):65.
   PubMedGoogle Scholar
• Kumar U, Kaur I, Dogra S, et al. Topical tazarotene vs. coal tar in stable plaque psoriasis. Clin Exp Dermatol. 2010;35(5):482–486.
   PubMed Web of Science ®Google Scholar
• Mehta BH, Amladi ST. Evaluation of topical 0.1% tazarotene cream in the treatment of palmoplantar psoriasis: an observer-blinded randomized controlled study. Indian J Dermatol. 2011;56(1):40–43.
   PubMedGoogle Scholar
• Weinstein GD, Koo JY, Krueger GG, et al. Tazarotene cream in the treatment of psoriasis: two multicenter, double-blind, randomized, vehicle-controlled studies of the safety and efficacy of tazarotene creams 0.05% and 0.1% applied once daily for 12 weeks. J Am Acad Dermatol. 2003;48(5):760–767.
   PubMed Web of Science ®Google Scholar
• Coynik D. Evaluating the potential clinical benefits of switching patients with plaque psoriasis from calcipotriene to tazarotene treatment. Cutis. 2000;66(6 Suppl):19–24.
   PubMedGoogle Scholar
• Tanghetti EA. An observation study evaluating the treatment of plaque psoriasis with tazarotene gels, alone and with an emollient and/or corticosteroid. Cutis. 2000;66(6 Suppl):4–11.
   PubMedGoogle Scholar
• Green L, Sadoff W. A clinical evaluation of tazarotene 0.1% gel, with and without a high- or mid-high-potency corticosteroid, in patients with stable plaque psoriasis. J Cutan Med Surg. 2002;6(2):95–102.
   PubMed Web of Science ®Google Scholar
• Koo JY, Martin D. Investigator-masked comparison of tazarotene gel q.d. plus mometasone furoate cream q.d. vs. mometasone furoate cream b.i.d. in the treatment of plaque psoriasis. Int J Dermatol. 2001;40(3):210–212.
   PubMed Web of Science ®Google Scholar
• Goodfield M, Kownacki S, Berth-Jones J. Double-blind, randomised, multicentre, parallel group study comparing a 1% coal tar preparation (Exorex) with a 5% coal tar preparation (Alphosyl) in chronic plaque psoriasis. J Dermatolog Treat. 2004;15(1):14–22.
   PubMedGoogle Scholar
• Swinkels OQJ, Prins M, Veenhuis RT, et al. Effectiveness and side effects of UVB-phototherapy, dithranol inpatient therapy and a care instruction programme of short contact dithranol in moderate to severe psoriasis. Eur J Dermatol. 2004;14(3):159–165.
   PubMed Web of Science ®Google Scholar
• Asbati M, Lugo AR, Reyes E, et al. Topic treatment of psoriasis: efficacy and safety of mometasone-salicilic acid ointment. Informe Medico. 2003;5(5):191–197.
   Google Scholar
• Stein LF, Sherr A, Solodkina G, et al. Betamethasone valerate foam for treatment of nonscalp psoriasis. J Cutan Med Surg. 2001;5(4):303–307.
   PubMed Web of Science ®Google Scholar
• Lambert J, Trompke C. Tacalcitol ointment for long-term control of chronic plaque psoriasis in dermatological practice. Dermatology. 2002;204(4):321–324.
   PubMed Web of Science ®Google Scholar
• Katoh N, Kishimoto S. Combination of calcipotriol and clobetasol propionate as a premixed ointment for the treatment of psoriasis. Eur J Dermatol. 2003;13(4):382–384.
   PubMed Web of Science ®Google Scholar
• Koo J, Blum RR, Lebwohl M. A randomized, multicenter study of calcipotriene ointment and clobetasol propionate foam in the sequential treatment of localized plaque-type psoriasis: short- and long-term outcomes. J Am Acad Dermatol. 2006;55(4):637–641.
   PubMed Web of Science ®Google Scholar
• Lee JH, Park CJ, Kim TY, et al. Optimal maintenance treatment with calcipotriol/betamethasone dipropionate gel in Korean patients with psoriasis vulgaris: a multicentre randomized, controlled clinical trial. J Eur Acad Dermatol Venereol. 2017;31(3):483–489.
   PubMed Web of Science ®Google Scholar
• Lebwohl M, Lombardi K, Tan MH. Duration of improvement in psoriasis after treatment with tazarotene 0.1% gel plus clobetasol propionate 0.05% ointment: comparison of maintenance treatments. Int J Dermatol. 2001;40(1):64–66.
   PubMed Web of Science ®Google Scholar
• Lambert J, Hol CW, Vink J. Real-life effectiveness of once-daily calcipotriol and betamethasone dipropionate gel vs. ointment formulations in psoriasis vulgaris: final analysis of the 52-week PRO-long study. J Eur Acad Dermatol Venereol. 2015;29(12):2349–2355.
   PubMed Web of Science ®Google Scholar
• Barnes L, Altmeyer P, Fôrstrôm L, et al. Long-term treatment of psoriasis with calcipotriol scalp solution and cream. European Journal of Dermatology. 2000;10(3):199–204.
   PubMed Web of Science ®Google Scholar
• Lebwohl M, Ortonne JP, Andres P, et al. Calcitriol ointment 3 microg/g is safe and effective over 52 weeks for the treatment of mild to moderate plaque psoriasis. Cutis. 2009;83(4):205–212.
   PubMed Web of Science ®Google Scholar
• Lebwohl M, Preston N, Gottschalk RW. Impact of baseline disease severity over 26 and 52 weeks of treatment with calcitriol ointment 3µg/g in patients with mild-to-moderate plaque psoriasis. J Clin Aesthet Dermatol. 2012;5(2):28–33.
   PubMedGoogle Scholar
• Miyachi Y, Ohkawara A, Ohkido M, et al. Long-term safety and efficacy of high-concentration (20 microg/g) tacalcitol ointment in psoriasis vulgaris. Eur J Dermatol. 2002;12(5):463–468.
   PubMed Web of Science ®Google Scholar
• Van de Kerkhof PCM, Berth-Jones J, Griffiths CEM, et al. Long-term efficacy and safety of tacalcitol ointment in patients with chronic plaque psoriasis. H + G Zeitschrift Fur Hautkrankheiten. 2002;77(9):424–432.
   Google Scholar
• Alinia H, Moradi Tuchayi S, Smith JA, et al. Long-term adherence to topical psoriasis treatment can be abysmal: a 1-year randomized intervention study using objective electronic adherence monitoring. Br J Dermatol. 2017;176(3):759–764.
   PubMed Web of Science ®Google Scholar
• Reich K, Zschocke I, Bachelez H, et al. A Topical Treatment Optimization Programme (TTOP) improves clinical outcome for calcipotriol/betamethasone gel in psoriasis: results of a 64-week multinational randomized phase IV study in 1790 patients (PSO-TOP). Br J Dermatol. 2017;177(1):197–205.
   PubMed Web of Science ®Google Scholar
• Reich K, Zschocke I, Bachelez H, et al. Efficacy of a fixed combination of calcipotriol/betamethasone dipropionate topical gel in adult patients with mild to moderate psoriasis: blinded interim analysis of a phase IV, multicenter, randomized, controlled, prospective study. J Eur Acad Dermatol Venereol. 2015;29(6):1156–1163.
   PubMed Web of Science ®Google Scholar
• Kragballe K, Austad J, Barnes L, et al. Efficacy results of a 52-week, randomised, double-blind, safety study of a calcipotriol/betamethasone dipropionate two-compound product (Daivobet/Dovobet/Taclonex) in the treatment of psoriasis vulgaris. Dermatology (Basel, switzerland). 2006;213(4):319–326.
   PubMed Web of Science ®Google Scholar
• Lebwohl M, Kircik L, Lacour JP, et al. Twice-weekly topical calcipotriene/betamethasone dipropionate foam as proactive management of plaque psoriasis increases time in remission and is well tolerated over 52 weeks (PSO-LONG trial). J Am Acad Dermatol. 2020;84(5):1269–1277.
   PubMed Web of Science ®Google Scholar
• Medicines.org.uk. Silkis 3 micrograms per g ointment - Summary of Product Characteristics (SmPC); 2020. [08/12/20]. Available from: https://www.medicines.org.uk/emc/product/1602
   Google Scholar
• Medicines.org.uk. Metosyn Ointment - Summary of Product Characteristics (SmPC); 2020 [08/12/20]. Available from: https://www.medicines.org.uk/emc/product/11392
   Google Scholar
• Medicines.org.uk. Dovobet gel - Summary of Product Characteristics (SmPC); 2020. [08/12/20]. Available from: https://www.medicines.org.uk/emc/product/5690/smpc
   Google Scholar
• Medicines.org.uk. Dovobet Ointment - Summary of Product Characteristics (SmPC); 2020. Available from: https://www.medicines.org.uk/emc/product/1609
   Google Scholar
• Medicines.org.uk. Curatoderm 4μg/g Ointment - Summary of Product Characteristics (SmPC); 2020. [08/12/20]. Available from: https://www.medicines.org.uk/emc/product/6389/smpc
   Google Scholar
• Medicines.org.uk. Zorac 0.05% Gel (tazarotene) - Summary of Product Characteristics (SmPC); 2020. [08/12/20]. Available from: https://www.medicines.org.uk/emc/product/6762/smpc
   Google Scholar
• Lebwohl M, Thaçi D, Warren RB. Addressing challenges associated with long-term topical treatment and benefits of proactive management in patients with psoriasis. J Eur Acad Dermatol Venereol. 2021;35 (Suppl 1):35–41.
   PubMedGoogle Scholar
• European Medicines Agency. CHMP Guildeline on clinical investigation of medicinal products indicated for the treatment of psoraisis. 2004.
   Google Scholar
• Lambert J, Hol CW, Vink J. Real-life effectiveness of once-daily calcipotriol and betamethasone dipropionate gel vs. ointment formulations in psoriasis vulgaris: 4- and 12-week interim results from the PRO-long study. J Eur Acad Dermatol Venereol. 2014;28(12):1723–1731.
   PubMed Web of Science ®Google Scholar
• Medicines.org.uk. Dovonex Ointment - Summary of Product Characteristics (SmPC); 2020 [08/12/20]. Available from: https://www.medicines.org.uk/emc/product/981/smpc
   Google Scholar